{"ticker": {"uuid": "cccd10cd-aa6f-40ab-ae9b-bfeca559f175", "symbol": "TARA", "name": "Protara Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What's Driving Protara's Recent Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBYaXYzd0g3T1RHLWYzUzRxOFZSdkdPdXU3QlVlY0gzUTVzYXBEMGkxV3F6dzdqWDI1S0UyNVBxMXJQMzVXYlluU1locUFNbUFDd3M0VXA1cl9KVTRYVzd0SXd3c3dLa1M3N09zekJLSGQ5UzRScmxWX2M2QWg?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-11T11:46:07+00:00", "published_display": "11 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group and Israel Englander report 5.7% stake in Protara (TARA)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a 5.7% stake in Protara Therapeutics (TARA), while Integrated Core Strategies (US) LLC reported a 5.1% stake. These entities collectively hold shared voting and dispositive power ove", "url": "https://www.stocktitan.net/sec-filings/TARA/schedule-13g-a-protara-therapeutics-inc-amended-passive-investment-di-015a4d6e71d4.html", "source_name": "Stock Titan", "published_at": "2026-07-07T22:41:50", "published_display": "07 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics focuses on rare disease programs as development continues", "summary": "Protara Therapeutics, a clinical-stage biopharmaceutical company, is advancing its rare and specialty disease pipeline. The company's stock value is heavily influenced by scientific milestones, strategic decisions, and capital market conditions, as it relies on existing cash and ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/protara-therapeutics-focuses-on-rare-disease-programs-as-development/69714374", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T13:12:11", "published_display": "07 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Protara Therapeutics, Inc. \u2013 NASDAQ:TARA", "summary": "This article provides the enterprise value to EBITDA forward for Protara Therapeutics, Inc. (NASDAQ: TARA). It's presented within a financial data context on a trading platform, indicating the company's valuation metric for investors. The content itself is minimalist, primarily s", "url": "https://www.tradingview.com/symbols/NASDAQ-TARA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T16:39:39", "published_display": "05 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Actuals & Estimates (HAM:1KPA)", "summary": "This article provides an overview of Protara Therapeutics, Inc. (HAM:1KPA) stock, including its financial actuals and estimates, price forecasts from analysts, and historical price performance. It details the company's past earnings, revenue, net income, and confirms that it does", "url": "https://www.tradingview.com/symbols/HAM-1KPA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-05T10:39:39", "published_display": "05 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Announces Key Medical Leadership Transition", "summary": "Protara Therapeutics announced the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, who is leaving to pursue other opportunities. His responsibilities will be transferred to Lead Medical Director Carla Beckham, under the continued oversight of Chief Research & De", "url": "https://www.tipranks.com/news/company-announcements/protara-therapeutics-announces-key-medical-leadership-transition", "source_name": "TipRanks", "published_at": "2026-07-02T21:48:39", "published_display": "02 Jul 2026 21:48", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA)", "summary": "This article examines analyst ratings for three healthcare companies: Sarepta Therapeutics (SRPT), Illumina (ILMN), and Protara Therapeutics (TARA). Sarepta Therapeutics has a Hold rating from Morgan Stanley with a $25.00 price target, and RBC Capital also maintains a Hold rating", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ILMN/pressreleases/3101233/analysts-conflicted-on-these-healthcare-names-sarepta-therapeutics-srpt-illumina-ilmn-and-protara-therapeutics-tara/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T11:41:00", "published_display": "02 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) CEO exercises options, sells 215,687 shares and makes 30,000-share gifts", "summary": "Protara Therapeutics CEO Jesse Shefferman exercised stock options to acquire 215,687 shares at $1.91 each and subsequently sold all of them for a weighted average price of $4.09 per share. He also made bona fide gift transfers of 30,000 shares. Following these transactions, Sheff", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-ba5205604151.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:19", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Protara Therapeutics, Inc. \u2013 GETTEX:1KPA", "summary": "This article provides financial information for Protara Therapeutics, Inc. (1KPA) on Gettex, specifically focusing on its enterprise value to EBITDA forward metric. The content indicates that the market is currently closed with no trades. The article is a financial data page from", "url": "https://www.tradingview.com/symbols/GETTEX-1KPA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T10:40:33", "published_display": "01 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics CMO Leonardo Viana Nicacio Resigns", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/protara-therapeutics-cmo-leonardo-viana-113036059.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:30:36+00:00", "published_display": "30 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 PROTARA THERAPEUTICS For: 29 June By Investing.com", "summary": "This article announces the filing of Form 144 for Protara Therapeutics (TARA) on June 29. Form 144 indicates an intent to sell restricted securities, which can sometimes impact a stock's short-term performance. The article provides only this brief, factual announcement from Inves", "url": "https://za.investing.com/news/stock-market-news/form-144-protara-therapeutics-for-29-june-93CH-4348784", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T06:39:31", "published_display": "30 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Protara Therapeutics, Inc. SEC Filing", "summary": "Protara Therapeutics, Inc. (TARA) has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details the sale of 215,687 common shares by Morgan Stanley Smith Barney LLC, acquired through a stock option exercise on June 29, 2026, with an aggregate mar", "url": "https://www.stocktitan.net/sec-filings/TARA/144-protara-therapeutics-inc-sec-filing-f8c732aa536d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:39", "published_display": "29 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) CMO Leonardo Nicacio resigns, duties reassigned", "summary": "Protara Therapeutics announced the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, M.D., effective June 26, 2026. His responsibilities will be absorbed by Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, under the supervision of Jacqu", "url": "https://www.stocktitan.net/sec-filings/TARA/8-k-protara-therapeutics-inc-reports-material-event-3a8f8c09ba90.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:39", "published_display": "29 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARA - Protara Therapeutics Inc Options", "summary": "This article provides detailed financial data and performance metrics for Protara Therapeutics Inc. (TARA), including its stock price, market capitalization, income, sales, key financial ratios, and insider/institutional ownership. It also lists EPS growth rates, analyst recommen", "url": "https://finviz.com/stock?t=TARA&p=m&r=max&ty=oc&ov=plot", "source_name": "Finviz", "published_at": "2026-06-29T20:09:38", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Actuals & Estimates (MUN:1KPA)", "summary": "This article provides an overview of Protara Therapeutics, Inc. (MUN:1KPA) financial data and analyst estimates, including actual results versus estimates, stock forecasts, and historical price movements. It also details the company's latest earnings, revenue, net income, and upc", "url": "https://www.tradingview.com/symbols/MUN-1KPA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:46", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Actuals & Estimates (FWB:1KPA)", "summary": "This article provides an overview of Protara Therapeutics, Inc. (FWB:1KPA) including its stock performance, financial estimates, and actual results. It details analyst forecasts for the stock price, historical highs and lows, and information regarding its earnings, revenue, and e", "url": "https://www.tradingview.com/symbols/FWB-1KPA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:59", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Protara Therapeutics, Inc. \u2013 FWB:1KPA", "summary": "This article provides financial information for Protara Therapeutics, Inc. (FWB:1KPA) on TradingView, specifically focusing on its enterprise value to revenue forward. The content indicates that the market is currently closed with no trades recorded for the company on the Frankfu", "url": "https://www.tradingview.com/symbols/FWB-1KPA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:39:46", "published_display": "26 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Protara Therapeutics, Inc. \u2013 NASDAQ:TARA", "summary": "The article provides an overview of Protara Therapeutics, Inc. (NASDAQ:TARA)'s enterprise value to revenue forward. It notes that the market for TARA is closed with no recent trades. The content primarily consists of navigation links and various product/community/company informat", "url": "https://www.tradingview.com/symbols/NASDAQ-TARA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:09:53", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Protara Therapeutics, Inc. \u2013 NASDAQ:TARA", "summary": "This article provides a financial snapshot for Protara Therapeutics, Inc. (NASDAQ: TARA), focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's platform, offering various market data and analysis tools for investors and traders. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-TARA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:09:47", "published_display": "25 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Protara Therapeutics Inc (TARA). It notes that relevant data for business segments and regional profit contributions have not yet been disclosed by the company for FY2019. The article highlights that the United States ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tara/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:03", "published_display": "18 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Inc (TARA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Protara Therapeutics Inc (TARA) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and there is no data available for past stock splits. The current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tara/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:03", "published_display": "18 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynthia Smith granted 31,000 stock options at Protara Therapeutics (TARA)", "summary": "Protara Therapeutics director Cynthia Smith was granted 31,000 stock options as equity compensation, with an exercise price of $3.94 per share. These options are set to vest fully on the first anniversary of the grant date, provided she continues her board service, and will also ", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-b405e18746a9.html", "source_name": "Stock Titan", "published_at": "2026-06-17T01:39:34", "published_display": "17 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) director awarded 31,000 stock options at $3.94 strike", "summary": "Protara Therapeutics director Michael Edward Solomon was granted 31,000 stock options with an exercise price of $3.94 per share. This grant, which vests fully on the first anniversary of the grant date or upon a Change of Control, allows him to purchase common stock and expires o", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-ef144fc90bd8.html", "source_name": "Stock Titan", "published_at": "2026-06-17T00:40:07", "published_display": "17 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) awards director 31,000 stock options at $3.94", "summary": "Protara Therapeutics director Gregory Sargen was granted 31,000 stock options with an exercise price of $3.94 per share, expiring on June 14, 2036. The options will vest in full on the first anniversary of the June 15, 2026 grant date or upon a Change of Control, provided Sargen ", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-f37fcc7241a1.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara (TARA) director granted 31,000 stock options at $3.94 strike", "summary": "Protara Therapeutics director Richard S. Levy was granted 31,000 stock options with an exercise price of $3.94 per share. These options are set to fully vest on the first anniversary of the grant date, provided he remains on the board, or immediately upon a Change of Control. Thi", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-b63e9531b558.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Protara Therapeutics (NASDAQ: TARA) awarded 31,000 stock options at $3.94", "summary": "Protara Therapeutics director Barry P. Flannelly was granted 31,000 stock options with an exercise price of $3.94 per share, expiring on June 14, 2036. The options will vest in full on the first anniversary of the June 15, 2026 grant date, provided the director continues to serve", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-a25b9c0c8254.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara (TARA) director receives 31,000 stock options at $3.94 strike", "summary": "Protara Therapeutics director Luke M. Beshar was granted 31,000 stock options with an exercise price of $3.94 per share. These options were issued as an Annual Grant and will vest fully on the first anniversary of the grant date, provided he continues his service on the board, or", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-ba7bc3873249.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jane Huang awarded 31,000 Protara (TARA) stock options as director grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUlBEUnF5aG5CVU9WZE9DYmotUlBQdTlnM1pRQzI4S2RsTDZuZjNXcTE3Q09rVndobmVxbktXbE9KNDljNUtqTDh2YTBUbnVtU3Q4ODBTN0VKdzlTWXFJMC0yWU9UeW5KSDM4QnR5OXNreVdNbzctdTNPUzk4M2UyNTFlWjZWMnJ6UG5tZW5MY0N5OGFlckpXeTYzenJpMFBGcWdqcXc5Mk5NM1dSQWVnZDdSRjh4OHpSR1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara (TARA) director awarded 31,000 options at $3.94 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPODNtcFdMOWNKOGRiRjlvc090VEVvYjVtNFdrbzNXSU5TRHhpcHNEZ3p0UUtjRFh0LVNLekhQazlrVkcxLTJRZkg2aGJPaVFLOS1BOENjUWlPNWRPUGs2eEZTZ0s2VDUzX0d5ZHBkWGZDRExUd3Z3cHRhanoteU1Oc2V2LS10MFJZV2dGaDdkYzJjX0xEYXJzMlNVRFJrbG9JX2lPQjdMZkVmXy1faWFVRS1nOThHZENLVHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) investors approve share increase and pay items", "summary": "Protara Therapeutics, Inc. (TARA) stockholders approved all seven proposals at their recent Annual Meeting, including the election of three Class III directors, the ratification of Ernst & Young LLP as auditor, and advisory approvals for executive compensation and an annual say-o", "url": "https://www.stocktitan.net/sec-filings/TARA/8-k-protara-therapeutics-inc-reports-material-event-a9192e7f91ab.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:09:04", "published_display": "15 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes", "summary": "Protara Therapeutics' Chief Commercial Officer, William Conkling, had 6,008 shares withheld by the company to cover income tax obligations related to the vesting of Restricted Stock Unit Awards. This transaction, valued at $4.34 per share, was an administrative tax-withholding di", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-f77db07a5969.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:10:08", "published_display": "03 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million", "summary": "", "url": "https://finance.yahoo.com/m/d135b7e2-bebc-3c6e-a288-2fe381db24d0/velan-capital-drops-140%2C000.html", "source_name": "Motley Fool", "published_at": "2026-05-31T14:39:50+00:00", "published_display": "31 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics - enters sales agreement with TD Cowen for common stock offering", "summary": "Protara Therapeutics has entered into a sales agreement with TD Cowen for a common stock offering. This news comes amidst other recent developments for the clinical-stage biotechnology company, including positive updated 12-month data from a Phase 2 trial of its lead candidate, T", "url": "https://www.marketscreener.com/news/protara-therapeutics-enters-sales-agreement-with-td-cowen-for-common-stock-offering-ce7f5ddad188ff20", "source_name": "marketscreener.com", "published_at": "2026-05-28T21:09:15", "published_display": "28 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (NASDAQ: TARA) secures $100M ATM sales agreement with TD Cowen", "summary": "Protara Therapeutics (NASDAQ: TARA) has entered into an at-the-market (ATM) sales agreement with TD Cowen to sell up to $100 million of its common stock. This offering is part of a larger $300 million shelf registration and the proceeds will primarily fund the clinical developmen", "url": "https://www.stocktitan.net/sec-filings/TARA/424b5-protara-therapeutics-inc-prospectus-supplement-debt-securities-cdda9bce7a2a.html", "source_name": "Stock Titan", "published_at": "2026-05-28T20:09:15", "published_display": "28 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oppenheimer-adjusts-protara-therapeutics-pt-122649975.html", "source_name": "MT Newswires", "published_at": "2026-05-20T12:26:49+00:00", "published_display": "20 May 2026 12:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/protara-therapeutics-present-td-cowen-120000396.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/protara-therapeutics-host-virtual-investor-120000150.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Na\u00efve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/protara-therapeutics-announces-positive-updated-110000757.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:00:00+00:00", "published_display": "15 May 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Protara Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/protara-therapeutics-q1-earnings-snapshot-120638309.html", "source_name": "Associated Press", "published_at": "2026-05-13T12:06:38+00:00", "published_display": "13 May 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxOejB0bzFMOW5qMUw1YXpPTlEtOEFlNTU3T2dPTDBlT1BfR2pPOHFxRDdyeHM5QXpmSl9vcHZZT3RFLUFsaE9rWTRZV2ppRlhjUmNXbTVDc1habE51SXB0M1BDRzVSci1NZmpIZjNCYzhOc3k1YWRnRzYzQTMta1RLb20xUnBUeUdBSWFVSU5HVkMyWDFNN25RVE05ZEVxLUl5aklqXzNJRUN3NUJxS094R0JHSmJ6WWlGcmpjSG5PcDdEc253ajN0dnFFVlpRUUdNSVZVNmx0eUw4dG9CZDM1c0NmVzZmTUllenlhOFBLZ0wzVEZkRlhiS1lDMTFtdGs?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "One Protara Therapeutics Insider Raised Their Stake In The Previous Year", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/one-protara-therapeutics-insider-raised-101508094.html", "source_name": "Simply Wall St.", "published_at": "2026-05-04T10:15:08+00:00", "published_display": "04 May 2026 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOMXFnWHVWMTJmaklLT1FBV0VNOWVSa1hXeTJqNEprdEtQNl81MS16VTQtcFl6dWJPUW91aEpHS0pJSmZONWFNV293NDIxWFpQcklDT1BFLVlMUTYzemJ0Vzl2NHRsdjhzaDhqV3g0MnVIeGZfZm5uaU5rdmNndU5EWGY3TVAweFlzSnFmZ3dEakxUZV9wUlRVbzNWYldORl8zYXl1N2EyemFHQmtTUlhIMWZRbm93bGFBUWJjcEFneld3cUcw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPSlBhOTdIY1phOUN5d01PbUF1WWVxdTlrclNSa240NDEyMFpjclNlN0pjMC15dy1aMkxJTlhNR1Q2d1M2blJKVnVPbmtLOWMtWkVibzdFYnZEZHVieWhlMENvZk10SmJ3ZUJDRmhqQmNKR2FpUy04bVJKNTZOZW16cm8yell5ZUk5ZENaQkxVNnBZTlN0Y0tkSU12RXRUMl9laTlqbEdtc19uQ3otOEhxd0sxQU9pOG8?oc=5", "source_name": "GuruFocus", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARA-002 results send Protara shares upwards", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOcFVjdXhvOFEteUNxNXpGeFpyM3UweTMyYVlybHdWZWZGNzN5RkNzNWZXeEZ4MjBYQTc3c2ExNEpvUlgxRFQ3MDFIVHBkbDBXMjE3MVFTeEh5WjVPWlZrY3dRMGZWNmduVzdKdjA3YnZKT3pYajRwUEFrVzVkVTF6U1ZwUTRvOF9DZ1MwYVpWUTRsU2c?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected after a year of 5.8% returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Common Stock (TARA) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE56amNjV3VsQlM5dHZhcmszT0UtOXI4aDZua1lTQjNKQmVRMUtaRC1DUTVsWEtQeXJrS3h5ZVdWbjJuNlRQeVpYTzFUekxRcEtuSjBTRjZQUQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:24:11+00:00", "published_display": "13 Jan 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA): Evaluating Valuation Following S&P Global BMI Index Inclusion", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-10T07:00:00+00:00", "published_display": "10 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARA SEC Filings - Protara Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE02emJ6Q080OURlSnU5UXZid0hlY0FvOHRma3pvelFsYmNONXpOMDBFMmMzci1EcHBrajl1LXZIV0E1NVl4cENhbnlINzhSM180eWxlTlBOYw?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-01T01:22:43+00:00", "published_display": "01 Jul 2025 01:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5UZTRYYWIyY3hPcDRhc2FkbVZEV0FyTmdJQmtLVVZ6UzJEMDBIMF8xRFRaN1FIREZKLWRkMTdWU0JRc1N2dUVDWVF5RHp3eGZpRHNV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:33:43+00:00", "published_display": "24 Apr 2025 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) Stock Price, News & Analysis $TARA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE01WnMyOXZiMGh6ZTlYck9QRkdvQmY4S3BRamFiTUdOY1o5UzNhb2YyWGNudzl1dXQyRlF1M1FRTWl6WnlNRUxzNzFkUEtoODdDVzZEU1ZUbHcxQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-01-22T13:15:27+00:00", "published_display": "22 Jan 2020 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "What's Driving Protara's Recent Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBYaXYzd0g3T1RHLWYzUzRxOFZSdkdPdXU3QlVlY0gzUTVzYXBEMGkxV3F6dzdqWDI1S0UyNVBxMXJQMzVXYlluU1locUFNbUFDd3M0VXA1cl9KVTRYVzd0SXd3c3dLa1M3N09zekJLSGQ5UzRScmxWX2M2QWg?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-11T11:46:07+00:00", "published_display": "11 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group and Israel Englander report 5.7% stake in Protara (TARA)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a 5.7% stake in Protara Therapeutics (TARA), while Integrated Core Strategies (US) LLC reported a 5.1% stake. These entities collectively hold shared voting and dispositive power ove", "url": "https://www.stocktitan.net/sec-filings/TARA/schedule-13g-a-protara-therapeutics-inc-amended-passive-investment-di-015a4d6e71d4.html", "source_name": "Stock Titan", "published_at": "2026-07-07T22:41:50", "published_display": "07 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics focuses on rare disease programs as development continues", "summary": "Protara Therapeutics, a clinical-stage biopharmaceutical company, is advancing its rare and specialty disease pipeline. The company's stock value is heavily influenced by scientific milestones, strategic decisions, and capital market conditions, as it relies on existing cash and ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/protara-therapeutics-focuses-on-rare-disease-programs-as-development/69714374", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T13:12:11", "published_display": "07 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Protara Therapeutics, Inc. \u2013 NASDAQ:TARA", "summary": "This article provides the enterprise value to EBITDA forward for Protara Therapeutics, Inc. (NASDAQ: TARA). It's presented within a financial data context on a trading platform, indicating the company's valuation metric for investors. The content itself is minimalist, primarily s", "url": "https://www.tradingview.com/symbols/NASDAQ-TARA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T16:39:39", "published_display": "05 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Actuals & Estimates (HAM:1KPA)", "summary": "This article provides an overview of Protara Therapeutics, Inc. (HAM:1KPA) stock, including its financial actuals and estimates, price forecasts from analysts, and historical price performance. It details the company's past earnings, revenue, net income, and confirms that it does", "url": "https://www.tradingview.com/symbols/HAM-1KPA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-05T10:39:39", "published_display": "05 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Announces Key Medical Leadership Transition", "summary": "Protara Therapeutics announced the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, who is leaving to pursue other opportunities. His responsibilities will be transferred to Lead Medical Director Carla Beckham, under the continued oversight of Chief Research & De", "url": "https://www.tipranks.com/news/company-announcements/protara-therapeutics-announces-key-medical-leadership-transition", "source_name": "TipRanks", "published_at": "2026-07-02T21:48:39", "published_display": "02 Jul 2026 21:48", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA)", "summary": "This article examines analyst ratings for three healthcare companies: Sarepta Therapeutics (SRPT), Illumina (ILMN), and Protara Therapeutics (TARA). Sarepta Therapeutics has a Hold rating from Morgan Stanley with a $25.00 price target, and RBC Capital also maintains a Hold rating", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ILMN/pressreleases/3101233/analysts-conflicted-on-these-healthcare-names-sarepta-therapeutics-srpt-illumina-ilmn-and-protara-therapeutics-tara/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T11:41:00", "published_display": "02 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) CEO exercises options, sells 215,687 shares and makes 30,000-share gifts", "summary": "Protara Therapeutics CEO Jesse Shefferman exercised stock options to acquire 215,687 shares at $1.91 each and subsequently sold all of them for a weighted average price of $4.09 per share. He also made bona fide gift transfers of 30,000 shares. Following these transactions, Sheff", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-ba5205604151.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:19", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Protara Therapeutics, Inc. \u2013 GETTEX:1KPA", "summary": "This article provides financial information for Protara Therapeutics, Inc. (1KPA) on Gettex, specifically focusing on its enterprise value to EBITDA forward metric. The content indicates that the market is currently closed with no trades. The article is a financial data page from", "url": "https://www.tradingview.com/symbols/GETTEX-1KPA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T10:40:33", "published_display": "01 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics CMO Leonardo Viana Nicacio Resigns", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/protara-therapeutics-cmo-leonardo-viana-113036059.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:30:36+00:00", "published_display": "30 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 PROTARA THERAPEUTICS For: 29 June By Investing.com", "summary": "This article announces the filing of Form 144 for Protara Therapeutics (TARA) on June 29. Form 144 indicates an intent to sell restricted securities, which can sometimes impact a stock's short-term performance. The article provides only this brief, factual announcement from Inves", "url": "https://za.investing.com/news/stock-market-news/form-144-protara-therapeutics-for-29-june-93CH-4348784", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T06:39:31", "published_display": "30 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Protara Therapeutics, Inc. SEC Filing", "summary": "Protara Therapeutics, Inc. (TARA) has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details the sale of 215,687 common shares by Morgan Stanley Smith Barney LLC, acquired through a stock option exercise on June 29, 2026, with an aggregate mar", "url": "https://www.stocktitan.net/sec-filings/TARA/144-protara-therapeutics-inc-sec-filing-f8c732aa536d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:39", "published_display": "29 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) CMO Leonardo Nicacio resigns, duties reassigned", "summary": "Protara Therapeutics announced the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, M.D., effective June 26, 2026. His responsibilities will be absorbed by Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, under the supervision of Jacqu", "url": "https://www.stocktitan.net/sec-filings/TARA/8-k-protara-therapeutics-inc-reports-material-event-3a8f8c09ba90.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:39", "published_display": "29 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARA - Protara Therapeutics Inc Options", "summary": "This article provides detailed financial data and performance metrics for Protara Therapeutics Inc. (TARA), including its stock price, market capitalization, income, sales, key financial ratios, and insider/institutional ownership. It also lists EPS growth rates, analyst recommen", "url": "https://finviz.com/stock?t=TARA&p=m&r=max&ty=oc&ov=plot", "source_name": "Finviz", "published_at": "2026-06-29T20:09:38", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Actuals & Estimates (MUN:1KPA)", "summary": "This article provides an overview of Protara Therapeutics, Inc. (MUN:1KPA) financial data and analyst estimates, including actual results versus estimates, stock forecasts, and historical price movements. It also details the company's latest earnings, revenue, net income, and upc", "url": "https://www.tradingview.com/symbols/MUN-1KPA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:46", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Actuals & Estimates (FWB:1KPA)", "summary": "This article provides an overview of Protara Therapeutics, Inc. (FWB:1KPA) including its stock performance, financial estimates, and actual results. It details analyst forecasts for the stock price, historical highs and lows, and information regarding its earnings, revenue, and e", "url": "https://www.tradingview.com/symbols/FWB-1KPA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:59", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Protara Therapeutics, Inc. \u2013 FWB:1KPA", "summary": "This article provides financial information for Protara Therapeutics, Inc. (FWB:1KPA) on TradingView, specifically focusing on its enterprise value to revenue forward. The content indicates that the market is currently closed with no trades recorded for the company on the Frankfu", "url": "https://www.tradingview.com/symbols/FWB-1KPA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:39:46", "published_display": "26 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Protara Therapeutics, Inc. \u2013 NASDAQ:TARA", "summary": "The article provides an overview of Protara Therapeutics, Inc. (NASDAQ:TARA)'s enterprise value to revenue forward. It notes that the market for TARA is closed with no recent trades. The content primarily consists of navigation links and various product/community/company informat", "url": "https://www.tradingview.com/symbols/NASDAQ-TARA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:09:53", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Protara Therapeutics, Inc. \u2013 NASDAQ:TARA", "summary": "This article provides a financial snapshot for Protara Therapeutics, Inc. (NASDAQ: TARA), focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's platform, offering various market data and analysis tools for investors and traders. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-TARA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:09:47", "published_display": "25 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Protara Therapeutics Inc (TARA). It notes that relevant data for business segments and regional profit contributions have not yet been disclosed by the company for FY2019. The article highlights that the United States ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tara/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:03", "published_display": "18 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Inc (TARA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Protara Therapeutics Inc (TARA) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and there is no data available for past stock splits. The current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tara/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:03", "published_display": "18 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynthia Smith granted 31,000 stock options at Protara Therapeutics (TARA)", "summary": "Protara Therapeutics director Cynthia Smith was granted 31,000 stock options as equity compensation, with an exercise price of $3.94 per share. These options are set to vest fully on the first anniversary of the grant date, provided she continues her board service, and will also ", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-b405e18746a9.html", "source_name": "Stock Titan", "published_at": "2026-06-17T01:39:34", "published_display": "17 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) director awarded 31,000 stock options at $3.94 strike", "summary": "Protara Therapeutics director Michael Edward Solomon was granted 31,000 stock options with an exercise price of $3.94 per share. This grant, which vests fully on the first anniversary of the grant date or upon a Change of Control, allows him to purchase common stock and expires o", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-ef144fc90bd8.html", "source_name": "Stock Titan", "published_at": "2026-06-17T00:40:07", "published_display": "17 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) awards director 31,000 stock options at $3.94", "summary": "Protara Therapeutics director Gregory Sargen was granted 31,000 stock options with an exercise price of $3.94 per share, expiring on June 14, 2036. The options will vest in full on the first anniversary of the June 15, 2026 grant date or upon a Change of Control, provided Sargen ", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-f37fcc7241a1.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara (TARA) director granted 31,000 stock options at $3.94 strike", "summary": "Protara Therapeutics director Richard S. Levy was granted 31,000 stock options with an exercise price of $3.94 per share. These options are set to fully vest on the first anniversary of the grant date, provided he remains on the board, or immediately upon a Change of Control. Thi", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-b63e9531b558.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Protara Therapeutics (NASDAQ: TARA) awarded 31,000 stock options at $3.94", "summary": "Protara Therapeutics director Barry P. Flannelly was granted 31,000 stock options with an exercise price of $3.94 per share, expiring on June 14, 2036. The options will vest in full on the first anniversary of the June 15, 2026 grant date, provided the director continues to serve", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-a25b9c0c8254.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara (TARA) director receives 31,000 stock options at $3.94 strike", "summary": "Protara Therapeutics director Luke M. Beshar was granted 31,000 stock options with an exercise price of $3.94 per share. These options were issued as an Annual Grant and will vest fully on the first anniversary of the grant date, provided he continues his service on the board, or", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-ba7bc3873249.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:50", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jane Huang awarded 31,000 Protara (TARA) stock options as director grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUlBEUnF5aG5CVU9WZE9DYmotUlBQdTlnM1pRQzI4S2RsTDZuZjNXcTE3Q09rVndobmVxbktXbE9KNDljNUtqTDh2YTBUbnVtU3Q4ODBTN0VKdzlTWXFJMC0yWU9UeW5KSDM4QnR5OXNreVdNbzctdTNPUzk4M2UyNTFlWjZWMnJ6UG5tZW5MY0N5OGFlckpXeTYzenJpMFBGcWdqcXc5Mk5NM1dSQWVnZDdSRjh4OHpSR1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara (TARA) director awarded 31,000 options at $3.94 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPODNtcFdMOWNKOGRiRjlvc090VEVvYjVtNFdrbzNXSU5TRHhpcHNEZ3p0UUtjRFh0LVNLekhQazlrVkcxLTJRZkg2aGJPaVFLOS1BOENjUWlPNWRPUGs2eEZTZ0s2VDUzX0d5ZHBkWGZDRExUd3Z3cHRhanoteU1Oc2V2LS10MFJZV2dGaDdkYzJjX0xEYXJzMlNVRFJrbG9JX2lPQjdMZkVmXy1faWFVRS1nOThHZENLVHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) investors approve share increase and pay items", "summary": "Protara Therapeutics, Inc. (TARA) stockholders approved all seven proposals at their recent Annual Meeting, including the election of three Class III directors, the ratification of Ernst & Young LLP as auditor, and advisory approvals for executive compensation and an annual say-o", "url": "https://www.stocktitan.net/sec-filings/TARA/8-k-protara-therapeutics-inc-reports-material-event-a9192e7f91ab.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:09:04", "published_display": "15 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes", "summary": "Protara Therapeutics' Chief Commercial Officer, William Conkling, had 6,008 shares withheld by the company to cover income tax obligations related to the vesting of Restricted Stock Unit Awards. This transaction, valued at $4.34 per share, was an administrative tax-withholding di", "url": "https://www.stocktitan.net/sec-filings/TARA/form-4-protara-therapeutics-inc-insider-trading-activity-f77db07a5969.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:10:08", "published_display": "03 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million", "summary": "", "url": "https://finance.yahoo.com/m/d135b7e2-bebc-3c6e-a288-2fe381db24d0/velan-capital-drops-140%2C000.html", "source_name": "Motley Fool", "published_at": "2026-05-31T14:39:50+00:00", "published_display": "31 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics - enters sales agreement with TD Cowen for common stock offering", "summary": "Protara Therapeutics has entered into a sales agreement with TD Cowen for a common stock offering. This news comes amidst other recent developments for the clinical-stage biotechnology company, including positive updated 12-month data from a Phase 2 trial of its lead candidate, T", "url": "https://www.marketscreener.com/news/protara-therapeutics-enters-sales-agreement-with-td-cowen-for-common-stock-offering-ce7f5ddad188ff20", "source_name": "marketscreener.com", "published_at": "2026-05-28T21:09:15", "published_display": "28 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (NASDAQ: TARA) secures $100M ATM sales agreement with TD Cowen", "summary": "Protara Therapeutics (NASDAQ: TARA) has entered into an at-the-market (ATM) sales agreement with TD Cowen to sell up to $100 million of its common stock. This offering is part of a larger $300 million shelf registration and the proceeds will primarily fund the clinical developmen", "url": "https://www.stocktitan.net/sec-filings/TARA/424b5-protara-therapeutics-inc-prospectus-supplement-debt-securities-cdda9bce7a2a.html", "source_name": "Stock Titan", "published_at": "2026-05-28T20:09:15", "published_display": "28 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oppenheimer-adjusts-protara-therapeutics-pt-122649975.html", "source_name": "MT Newswires", "published_at": "2026-05-20T12:26:49+00:00", "published_display": "20 May 2026 12:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/protara-therapeutics-present-td-cowen-120000396.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/protara-therapeutics-host-virtual-investor-120000150.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Na\u00efve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/protara-therapeutics-announces-positive-updated-110000757.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:00:00+00:00", "published_display": "15 May 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/protara-therapeutics-q1-earnings-snapshot-120638309.html", "source_name": "Associated Press", "published_at": "2026-05-13T12:06:38+00:00", "published_display": "13 May 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxOejB0bzFMOW5qMUw1YXpPTlEtOEFlNTU3T2dPTDBlT1BfR2pPOHFxRDdyeHM5QXpmSl9vcHZZT3RFLUFsaE9rWTRZV2ppRlhjUmNXbTVDc1habE51SXB0M1BDRzVSci1NZmpIZjNCYzhOc3k1YWRnRzYzQTMta1RLb20xUnBUeUdBSWFVSU5HVkMyWDFNN25RVE05ZEVxLUl5aklqXzNJRUN3NUJxS094R0JHSmJ6WWlGcmpjSG5PcDdEc253ajN0dnFFVlpRUUdNSVZVNmx0eUw4dG9CZDM1c0NmVzZmTUllenlhOFBLZ0wzVEZkRlhiS1lDMTFtdGs?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Protara Therapeutics Insider Raised Their Stake In The Previous Year", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/one-protara-therapeutics-insider-raised-101508094.html", "source_name": "Simply Wall St.", "published_at": "2026-05-04T10:15:08+00:00", "published_display": "04 May 2026 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOMXFnWHVWMTJmaklLT1FBV0VNOWVSa1hXeTJqNEprdEtQNl81MS16VTQtcFl6dWJPUW91aEpHS0pJSmZONWFNV293NDIxWFpQcklDT1BFLVlMUTYzemJ0Vzl2NHRsdjhzaDhqV3g0MnVIeGZfZm5uaU5rdmNndU5EWGY3TVAweFlzSnFmZ3dEakxUZV9wUlRVbzNWYldORl8zYXl1N2EyemFHQmtTUlhIMWZRbm93bGFBUWJjcEFneld3cUcw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPSlBhOTdIY1phOUN5d01PbUF1WWVxdTlrclNSa240NDEyMFpjclNlN0pjMC15dy1aMkxJTlhNR1Q2d1M2blJKVnVPbmtLOWMtWkVibzdFYnZEZHVieWhlMENvZk10SmJ3ZUJDRmhqQmNKR2FpUy04bVJKNTZOZW16cm8yell5ZUk5ZENaQkxVNnBZTlN0Y0tkSU12RXRUMl9laTlqbEdtc19uQ3otOEhxd0sxQU9pOG8?oc=5", "source_name": "GuruFocus", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARA-002 results send Protara shares upwards", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOcFVjdXhvOFEteUNxNXpGeFpyM3UweTMyYVlybHdWZWZGNzN5RkNzNWZXeEZ4MjBYQTc3c2ExNEpvUlgxRFQ3MDFIVHBkbDBXMjE3MVFTeEh5WjVPWlZrY3dRMGZWNmduVzdKdjA3YnZKT3pYajRwUEFrVzVkVTF6U1ZwUTRvOF9DZ1MwYVpWUTRsU2c?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected after a year of 5.8% returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics, Inc. Common Stock (TARA) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE56amNjV3VsQlM5dHZhcmszT0UtOXI4aDZua1lTQjNKQmVRMUtaRC1DUTVsWEtQeXJrS3h5ZVdWbjJuNlRQeVpYTzFUekxRcEtuSjBTRjZQUQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:24:11+00:00", "published_display": "13 Jan 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA): Evaluating Valuation Following S&P Global BMI Index Inclusion", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-10T07:00:00+00:00", "published_display": "10 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARA SEC Filings - Protara Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE02emJ6Q080OURlSnU5UXZid0hlY0FvOHRma3pvelFsYmNONXpOMDBFMmMzci1EcHBrajl1LXZIV0E1NVl4cENhbnlINzhSM180eWxlTlBOYw?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-01T01:22:43+00:00", "published_display": "01 Jul 2025 01:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5UZTRYYWIyY3hPcDRhc2FkbVZEV0FyTmdJQmtLVVZ6UzJEMDBIMF8xRFRaN1FIREZKLWRkMTdWU0JRc1N2dUVDWVF5RHp3eGZpRHNV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:33:43+00:00", "published_display": "24 Apr 2025 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protara Therapeutics (TARA) Stock Price, News & Analysis $TARA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE01WnMyOXZiMGh6ZTlYck9QRkdvQmY4S3BRamFiTUdOY1o5UzNhb2YyWGNudzl1dXQyRlF1M1FRTWl6WnlNRUxzNzFkUEtoODdDVzZEU1ZUbHcxQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-01-22T13:15:27+00:00", "published_display": "22 Jan 2020 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 59, "sentiment_summary": {"positive": 8, "negative": 4, "neutral": 47, "score": 51, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 9.7, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 4.32, "latest_week": "2026-07-10", "one_week_move": 6.4, "four_week_move": 10.8, "twelve_week_move": -20.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.454126, "market_dynamics_buy_signal": false, "relative_strength": -24.680512, "fair_value_gap": 20.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 44.7449, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.4% over one week, +10.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 17}, {"label": "TradingView", "count": 8}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "MT Newswires", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "Kavout | AI", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 19}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.4% over one week, +10.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "What's Driving Protara's Recent Surge"}], "updated_at": "2026-07-18T06:35:07.686904+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}